{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Greenstein YY"],"funding":["NHLBI NIH HHS","National Heart, Lung, and Blood Institute","National Institutes of Health","NIH"],"pagination":["785-799"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11026170"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["165(4)"],"pubmed_abstract":["<h4>Background</h4>Therapeutic-dose heparin decreased days requiring organ support in noncritically ill patients hospitalized for COVID-19, but its impact on persistent symptoms or quality of life (QOL) is unclear.<h4>Research question</h4>In the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4a) trial, was randomization of patients hospitalized for COVID-19 illness to therapeutic-dose vs prophylactic heparin associated with fewer symptoms and better QOL at 90 days?<h4>Study design and methods</h4>This was an open-label randomized controlled trial at 34 hospitals in the United States and Spain. A total of 727 noncritically ill patients hospitalized for COVID-19 from September 2020 to June 2021 were randomized to therapeutic-dose vs prophylactic heparin. Only pa"],"journal":["Chest"],"pubmed_title":["Symptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial: Effect on 3-Month Symptoms and Quality of Life."],"pmcid":["PMC11026170"],"funding_grant_id":["1OT2HL156812-01","OT2 HL156812","OTA-20-011"],"pubmed_authors":["Colovos C","Froess J","Chang SY","Shah F","Gaddh M","Lai YH","Berger JS","Guerrero RM","Venugopal V","Wisniewski SR","Huang DT","Goligher EC","Nkemdirim W","Lopes RD","Hubel K","Lawler PR","Kornblith LZ","Leifer E","Greenstein YY","Hochman JS","Gong MN","Cushman M","Wahid L","Zahra A","Zarychanski R","Amigo JS","Neal MD","Reynolds HR"],"additional_accession":[]},"is_claimable":false,"name":"Symptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial: Effect on 3-Month Symptoms and Quality of Life.","description":"<h4>Background</h4>Therapeutic-dose heparin decreased days requiring organ support in noncritically ill patients hospitalized for COVID-19, but its impact on persistent symptoms or quality of life (QOL) is unclear.<h4>Research question</h4>In the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4a) trial, was randomization of patients hospitalized for COVID-19 illness to therapeutic-dose vs prophylactic heparin associated with fewer symptoms and better QOL at 90 days?<h4>Study design and methods</h4>This was an open-label randomized controlled trial at 34 hospitals in the United States and Spain. A total of 727 noncritically ill patients hospitalized for COVID-19 from September 2020 to June 2021 were randomized to therapeutic-dose vs prophylactic heparin. Only pa","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T07:45:46.832Z","creation":"2025-07-04T03:05:45.627Z"},"accession":"S-EPMC11026170","cross_references":{"pubmed":["37979717"],"doi":["10.1016/j.chest.2023.11.019"]}}